<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="92392">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01885754</url>
  </required_header>
  <id_info>
    <org_study_id>20878</org_study_id>
    <nct_id>NCT01885754</nct_id>
  </id_info>
  <brief_title>Characterization of Peripheral Muscle Function in Patients With Non-small-cell Lung Cancer</brief_title>
  <official_title>Characterization of Peripheral Muscle Function in Patients With Non-small-cell Lung Cancer.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre de Recherche de l'Institut Universitaire de Cardiologie et de Pneumologie de Quebec</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Centre de Recherche de l'Institut Universitaire de Cardiologie et de Pneumologie de Quebec</source>
  <oversight_info>
    <authority>Canada: Ethics Review Committee</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Rationale: With 1.6 million new cases diagnosed each year and 1.3 million deaths, lung
      cancer is the leading cancer-related death worldwide and it represents a pressing health
      issue. Patients with lung cancer are more likely to experience cachexia, a severe
      debilitating disorder causing fatigue, weight loss, muscle wasting and associated with
      reduced physical function, increased chemotherapy toxicity and reduced survival. This
      syndrome occurring in about 80% of advanced cancer patients is the direct cause of death in
      about 20% of cases. However, despite the importance of cachexia in lung cancer, its
      mechanisms ans its relation with muscle function and effort tolerance are still unknown.

      Aim: To explore muscle function, signaling pathways and its relationship to impaired
      functional capacity of patients with non-small-cell lung cancer(NSCLC); depending of whether
      they have cachexic state at diagnosis.

      Methods: This study will be conducted at the Institut universitaire de cardiologie et de
      pneumologie de Québec. 56 patients newly diagnosed of NSCLC will be recruited and separated
      whether or not they have a cachexic state. The evaluation will need two visits separated by
      5 days.

      During the evaluation the following tests will be done:

        -  Anthropometric measures

        -  Level of daily physical activity

        -  Pulmonary function test

        -  Maximal incremental cardiopulmonary exercise test on ergocycle

        -  Endurance test on ergocycle

        -  Muscle function tests

        -  Magnetic stimulation

        -  Quadriceps biopsy
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>February 2013</start_date>
  <completion_date type="Anticipated">May 2015</completion_date>
  <primary_completion_date type="Anticipated">May 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational</study_type>
  <study_design>Observational Model: Cohort, Time Perspective: Prospective</study_design>
  <primary_outcome>
    <measure>Maximal quadriceps strength</measure>
    <time_frame>1 day (at the time of the diagnosis before any treatment)</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Exercise capacity</measure>
    <time_frame>1 day  (at the time of the diagnosis before any treatment)</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">56</enrollment>
  <condition>Non-Small-cell Lung Cancer</condition>
  <arm_group>
    <arm_group_label>Lung cancer patient with cachexia</arm_group_label>
    <description>Muscle lumbar area &lt; 55cm2/m2 for men and &lt; 39 cm2/m2 for women</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Lung cancer patients without cachexia</arm_group_label>
    <description>Muscle lumbar area over 55cm2/m2 for men and 39 cm2/m2 for women</description>
  </arm_group>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Quadriceps Biopsy
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with NSCLC
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Men and women with a primary lung cancer diagnosis

        Exclusion Criteria:

          -  Already have undertaken surgery, chemotherapy or radiotherapy treatment

          -  Having an other cancer in the last five years

          -  Taking anticoagulation therapy
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Didier Saey, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Centre de Recherche de l'Institut Universitaire de Cardiologie et de Pneumologie de Quebec</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Institut universitaire de cardiologie et de pneumologie de Québec</name>
      <address>
        <city>Québec</city>
        <state>Quebec</state>
        <zip>G1V 4G5</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Didier Saey, PhD</last_name>
      <phone>418-656-8711</phone>
      <phone_ext>2614</phone_ext>
      <email>didier.saey@criucpq.ulaval.ca</email>
    </contact>
    <investigator>
      <last_name>Didier Saey, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>June 2013</verification_date>
  <lastchanged_date>June 24, 2013</lastchanged_date>
  <firstreceived_date>February 13, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Centre de Recherche de l'Institut Universitaire de Cardiologie et de Pneumologie de Quebec</investigator_affiliation>
    <investigator_full_name>Didier Saey</investigator_full_name>
    <investigator_title>PhD</investigator_title>
  </responsible_party>
  <keyword>Biopsy</keyword>
  <keyword>Maximal incremental cardiopulmonary test</keyword>
  <keyword>Muscle strength test</keyword>
  <keyword>magnetic stimulation</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
    <mesh_term>Lung Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
